Menu
Skip to content
Home
About
Management Team
Board of Directors
Pipeline
ENAC PULMONARY (VX-371/P-1037)
tPAD
Mucolytic Agents
CFTR Corrector Program for CF
P-321 Dry Eye Disease
Clinical Trials
News and Events
Partnerships
Careers
Contact
Search for:
Parion Sciences
bout
pipeline
newsslide
Home
Parion Sciences
Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses.
The epithelial surface plays an important role in keeping our bodies healthy. Parion’s science driven technologies target respiratory, ocular and other epithelial diseases resulting from deficiencies of the innate host defenses.
PIPELINE
ENAC PULMONARY (VX-371/P-1037)
tPAD
Mucolytic Agents
CFTR Corrector Program for CF
P-321 Dry Eye Disease
CLINICAL TRIALS
Learn More…
ABOUT PARION
ABOUT US
 learn more…
PARTNERSHIPS
 learn more…
CAREERS
 learn more…
CONTACT US
 learn more…
RECENT POSTS
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Topical ENaC blocker serves as novel approach to tear film
Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference
Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease
Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)
Ceva and Zoion Pharma Announce Collaboration to Develop Epithelial Sodium Channel Blockers to Treat Veterinary Ocular Surface Diseases
Parion Sciences Announces Upcoming Presentations of Data at the North American Cystic Fibrosis Conference Being Held October 8 through 10, 2015
CLEAN-CF Clinical Trial Expanded to Include Pediatric Cystic Fibrosis Population
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Parion Sciences Receives 2015 Life Sciences Award as “Best Late Stage Product Development” Company
Search for:
Recent Posts
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Topical ENaC blocker serves as novel approach to tear film
Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference
Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease
Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)
Recent Comments
Archives
May 2017
November 2016
October 2016
July 2016
May 2016
January 2016
October 2015
September 2015
June 2015
May 2015
February 2015
November 2014
October 2014
September 2014
June 2014
May 2014
April 2014
November 2013
Categories
News & Event
Uncategorized
Meta
Log in
Entries 
RSS
Comments 
RSS
WordPress.org
Home
 | 
About
 | 
Pipeline
 | 
News & Events
 | 
Partnerships
 | 
Careers
 | 
Contact
Copyright © 2017. All Rights Reserved.
Main menu